South Korea
· Delayed Price · Currency is KRW Korean Drug Statistics
Total Valuation
Korean Drug has a market cap or net worth of KRW 54.56 billion. The enterprise value is 36.62 billion.
| Market Cap | 54.56B |
| Enterprise Value | 36.62B |
Important Dates
The next estimated earnings date is Wednesday, November 27, 2024.
| Earnings Date | Nov 27, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Korean Drug has 10.91 million shares outstanding. The number of shares has decreased by -0.21% in one year.
| Shares Outstanding | 10.91M |
| Shares Change (YoY) | -0.21% |
| Shares Change (QoQ) | +0.03% |
| Owned by Insiders (%) | 50.60% |
| Owned by Institutions (%) | 0.02% |
| Float | 5.39M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 0.69 |
| PB Ratio | 0.69 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 9.96, with an EV/FCF ratio of -2.65.
| EV / Earnings | -29.48 |
| EV / Sales | 0.47 |
| EV / EBITDA | 9.96 |
| EV / EBIT | 21.90 |
| EV / FCF | -2.65 |
Financial Position
The company has a current ratio of 5.96, with a Debt / Equity ratio of 0.00.
| Current Ratio | 5.96 |
| Quick Ratio | 4.00 |
| Debt / Equity | 0.00 |
| Debt / EBITDA | 0.02 |
| Debt / FCF | -0.01 |
| Interest Coverage | 410.77 |
Financial Efficiency
Return on equity (ROE) is -1.56% and return on invested capital (ROIC) is 1.31%.
| Return on Equity (ROE) | -1.56% |
| Return on Assets (ROA) | 1.06% |
| Return on Capital (ROIC) | 1.31% |
| Revenue Per Employee | 288.60M |
| Profits Per Employee | -4.60M |
| Employee Count | 270 |
| Asset Turnover | 0.79 |
| Inventory Turnover | 2.25 |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -24.13% in the last 52 weeks.
| Beta (5Y) | n/a |
| 52-Week Price Change | -24.13% |
| 50-Day Moving Average | 5,198.20 |
| 200-Day Moving Average | 6,124.70 |
| Relative Strength Index (RSI) | 41.81 |
| Average Volume (20 Days) | 11,382 |
Short Selling Information
| Short Interest | n/a |
| Short Previous Month | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Korean Drug had revenue of KRW 77.92 billion and -1.24 billion in losses. Loss per share was -115.33.
| Revenue | 77.92B |
| Gross Profit | 37.34B |
| Operating Income | 1.67B |
| Pretax Income | 2.62B |
| Net Income | -1.24B |
| EBITDA | 3.68B |
| EBIT | 1.67B |
| Loss Per Share | -115.33 |
Balance Sheet
The company has 18.02 billion in cash and 77.94 million in debt, giving a net cash position of 17.94 billion or 1,644.08 per share.
| Cash & Cash Equivalents | 18.02B |
| Total Debt | 77.94M |
| Net Cash | 17.94B |
| Net Cash Per Share | 1,644.08 |
| Equity (Book Value) | 77.68B |
| Book Value Per Share | 7,199.81 |
| Working Capital | 55.99B |
Cash Flow
In the last 12 months, operating cash flow was -10.69 billion and capital expenditures -3.14 billion, giving a free cash flow of -13.83 billion.
| Operating Cash Flow | -10.69B |
| Capital Expenditures | -3.14B |
| Free Cash Flow | -13.83B |
| FCF Per Share | -1,267.34 |
Margins
Gross margin is 47.92%, with operating and profit margins of 2.15% and -1.59%.
| Gross Margin | 47.92% |
| Operating Margin | 2.15% |
| Pretax Margin | 3.36% |
| Profit Margin | -1.59% |
| EBITDA Margin | 4.72% |
| EBIT Margin | 2.15% |
| FCF Margin | -17.75% |
Dividends & Yields
This stock pays an annual dividend of 150.00, which amounts to a dividend yield of 3.00%.
| Dividend Per Share | 150.00 |
| Dividend Yield | 3.00% |
| Dividend Growth (YoY) | -16.67% |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | 0.21% |
| Shareholder Yield | 3.21% |
| Earnings Yield | -2.31% |
| FCF Yield | -25.35% |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Korean Drug has an Altman Z-Score of 5.64.
| Altman Z-Score | 5.64 |
| Piotroski F-Score | n/a |